Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Engage
Data as at: 07/11/2024
In
Objective
To seek capital appreciation through investment in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis.
AIC sector
Management group
Company website
Launch date
23/06/1997
March
Domicile
United Kingdom
Fund manager
Josh Golomb, Geoffrey C. Hsu
Dividend frequency
Data Not Available
Wind-up provisions
An opportunity to vote on the continuation of the Company is given to shareholders every five years. The next such continuation vote will be held at the AGM to be held in 2025.
Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
---|---|---|---|---|---|---|---|---|
327.84 | 376.46 | 1,036.00 | 1,103.84 | -6.15 | 3 | 0.00 | N/A | 1.2 (31/03/2024) |
Scroll
Dividends
Dividends declared in last 12 months
There have been no dividends in the last 12 months.
Performance (%)
Return type | 1 year | 3 years | 5 years | 10 years | |
---|---|---|---|---|---|
Biotech Growth Trust | Share price total return | 35.3 | -15.5 | 39.6 | 68.3 |
Biotechnology & Healthcare AIC sector | Share price total return | 14.3 | -16.5 | 6.3 | 93.6 |
Scroll
Share structure
Number of shares
31,644,676
Traded volumes (number of shares)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 65,318 | 1,962,870 | 17,838,678 | 109,942,206 |
Average | N/A | 78,224 | 70,149 | 87,155 |
Scroll
Traded values (m)
Yesterday | 1 month | 1 year | 5 years | |
---|---|---|---|---|
Total | 0.68 | 20.29 | 170.51 | 1,173.63 |
Average | N/A | 0.81 | 0.67 | 0.93 |
Scroll
Trading details
Top holdings
Data as at : 31/07/2024
Investment | % of total assets |
---|---|
Amgen Inc | 9.1 |
Other Assets And Liabilities | 6.6 |
Biogen Inc | 4.7 |
Sarepta Therapeutics Inc | 4.6 |
QuantumPharm Inc | 3.4 |
argenx SE ADR | 3.4 |
Regeneron Pharmaceuticals Inc | 3.3 |
ACADIA Pharmaceuticals Inc | 3.1 |
Syndax Pharmaceuticals Inc | 3.1 |
Alnylam Pharmaceuticals Inc | 2.9 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.